TWO · 7427.TWO
Great Novel Therapeutics Biotech & Medicals
NT$64.00+NT$0.90 (+1.43%)
Great Novel Therapeutics Biotech & Medicals’s quoted price sits in the upper half of its reported 52-week range, 22.71% below the high.
Loading market information…
TWO · 6496.TWO · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
Excelsior Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 24.06% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Excelsior Biopharma Inc.’s forward annual dividend is NT$1.00 per share, paid annual. The forward yield is 4.31% at the quoted price. Future payments can change.
Dividend payment history is currently unavailable.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Excelsior Biopharma Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Excelsior Biopharma Inc., established in 1988 and headquartered in Taipei, Taiwan, functions as a pharmaceutical enterprise with a global market presence, encompassing Taiwan, China, and other international regions. The company offers a comprehensive range of healthcare solutions, including prescription and over-the-counter medications, medical devices, nutritional supplements, and various medical supplies. Excelsior addresses numerous therapeutic areas such as pediatrics, gastroenterology, neurology, cardiology, dermatology, medical toxicology, dentistry, obstetrics, oncology, hematology, otorhinolaryngology, and infectious disease management. Its product line also features specialized diagnostic kits under the Actim brand for identifying conditions like influenza virus, fecal occult blood, acute pancreatitis, and for assessing preterm or full-week delivery and early membrane rupture. Moreover, the company provides oral hygiene products, including toothpaste, mouthwash, and gels, under the Oral7 name. Beyond product sales, Excelsior is involved in the import and export of active pharmaceutical ingredients, as well as engaging in technological research, facilitating pharmaceutical technology transfer, and participating in collaborative development and improvement initiatives. The company adopted its current name, Excelsior Biopharma Inc., in June 2003, having previously been known as Excelsior Enterprise Co., Ltd.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:07 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$64.00+NT$0.90 (+1.43%)
Great Novel Therapeutics Biotech & Medicals’s quoted price sits in the upper half of its reported 52-week range, 22.71% below the high.
NT$34.85-NT$1.95 (-5.3%)
Tien Liang BioTech Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 63.7% below the high.
NT$19.70-NT$0.60 (-2.96%)
Anxo Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.57% below the high.
NT$13.80-NT$0.20 (-1.43%)
MegaPro Biomedical Co., Ltd’s quoted price sits in the upper half of its reported 52-week range, 19.06% below the high.
NT$27.15-NT$1.35 (-4.74%)
Prince Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 19.67% below the high.
NT$6.40-NT$0.31 (-4.62%)
Holy Stone Healthcare Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 36.32% below the high.
NT$16.35-NT$0.30 (-1.8%)
GeneReach Biotechnology Corp.’s quoted price sits in the lower half of its reported 52-week range, 36.99% below the high.
NT$36.20-NT$0.20 (-0.55%)
DV Biomed Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 40.46% below the high.
